Literature DB >> 11043845

Male breast cancer. Does the prognosis differ compared to female?

K Herman1, W Lobaziewicz, P Skotnicki, J Fortuna, T Kusy, T Leśniak.   

Abstract

Due to the low incidence of breast cancer in males there are not many reports in the literature. In this study we analyzed results of treatment in 65 breast cancer males, who had been treated in one institution. Radical surgery was performed in 45 patients. Lymph node metastases were found in 25 patients (55.5%), the tumor was usually moderately differentiated (21 pts - 46.7%). Median survival after radical surgery was 73 months compared to 38 months for nonsurgical patients (p < 0.0001). In the group of males after radical surgery the results of 5-, 10- and 15-year survival rates were 69.8, 59.7 and 31.3% respectively. Comparable analysis of two subgroups of patients with favorable (T1 or T2, N0, grade I or II) and unfavorable (T3 or N+ or grade III) prognostic factors was also performed. In the first subgroup the 5-, 10- and 15-year survival rates were 90, 77.4 and 62%, compared to 61.8, 23.1 and 23. 1% for the second subgroup. The multivariate analysis showed grading and node status as the strongest parameters influencing survival. Relative risk of death was over 3 times higher for nodal metastases and near 3 times higher for high grade carcinomas (p < 0.01), compared to patients without metastases and low grade of tumor. Similar analysis was performed when 45 males were compared to 500 selected women, with similar clinical parameters (age, node status, grading). Again, data indicated grading and lymph node status as the strongest prognostic factors. It was not unlikely, that gender had some influence on prognosis, when relative risk of death for males was over 1.5 times higher than for females, but this result was not clearly significant (p < 0.1 ). The question, whether male breast cancer prognosis is worse then in female remains open. Multiinstitutional prospective studies are needed in this area.

Entities:  

Mesh:

Year:  2000        PMID: 11043845

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  2 in total

1.  Male breast cancer: thirteen years experience of a single center.

Authors:  Sami Akbulut; Ilker Arer; Alper Kocbiyik; Mahmut Can Yağmurdur; Hamdi Karakayalı; Mehmet Haberal
Journal:  Int Semin Surg Oncol       Date:  2009-02-05

Review 2.  Male breast cancer: is the scenario changing.

Authors:  Kaiyumars B Contractor; Kanchan Kaur; Gabriel S Rodrigues; Dhananjay M Kulkarni; Hemant Singhal
Journal:  World J Surg Oncol       Date:  2008-06-16       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.